Vimarsana
Biggest News Aggregation in the World

Page 5 - Georg Schett News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Georg Schett. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Georg Schett Today - Breaking & Trending Today

More Success for CAR T-Cell Therapy in Rheumatic Disease - Vimarsana News

More Success for CAR T-Cell Therapy in Rheumatic Disease

Stunning improvement for two patients with rare form of autoimmune myositis

B-cell system reset in CAR T-cell therapy 'feasible,' leads to durable remission in lupus - Vimarsana News

B-cell system reset in CAR T-cell therapy 'feasible,' leads to durable remission in lupus

In patients with systemic lupus erythematous, CAR T-cell therapy appears to be a feasible and effective method of achieving durable remission, according to a speaker at the Biologic Therapies Summit.“Lupus patients often need quite substantial amounts of glucocorticoids to stay in remission, and that is a huge problem,” Georg Schett, MD, of Friedrich-Alexander University, in Germany,

Source: healio.com
Cabaletta Bio : Corporate Presentation - Vimarsana News

Cabaletta Bio : Corporate Presentation

Corporate Presentation MAY 2023 © 2023 Cabaletta Bio. All rights reserved. ... | May 1, 2023

Amgen Inc. v. Sandoz Inc. (Fed. Cir. 2023) | McDonnell Boehnen Hulbert & Berghoff LLP - Vimarsana News

Amgen Inc. v. Sandoz Inc. (Fed. Cir. 2023) | McDonnell Boehnen Hulbert & Berghoff LLP

An appellant's burden on appeal is never easy but it is particularly difficult when the questions at issue are based on factual evidence.  The appellate judiciary is loathe (generally)...

Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update - Vimarsana News

Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

16.03.2023 - – Company expecting Investigational New Drug (IND) clearance in the first half of 2023 for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell therapy, with potential to generate initial clinical data by the first half of 2024 – PHILADELPHIA, ...